Additionally, UGCG activity could also be linked to other colon cancer cell resistance mechanisms; recently, it has been shown that inhibition of UGCG sensitizes colon adenocarcinoma SW480 cells, bearing a missense p53 mutation, to doxorubicin [50]. Here, TP53 is linked to colonic neoplasm.